In a report released today, Irina Rivkind Koffler from Mizuho Securities reiterated a Buy rating on Supernus Pharmaceuticals (SUPN). The company’s shares closed yesterday at $33.59, close to its 52-week low of $30.05.
Rivkind Koffler commented:
“We lowered our PT to $59 from $63 based on a lower revenue forecast of the existing neurology products. However, we continue to like SUPN longer- term based on the value of its ADHD pipeline, and reasonable risk/reward for SPN-810 in impulsive aggression. We reiterate our Buy rating.”
According to TipRanks.com, Koffler is a 1-star analyst with an average return of -1.1% and a 36.9% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Bausch Health Companies Inc, and Assertio Therapeutics Inc.
Supernus Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $61, implying an 81.6% upside from current levels. In a report issued on May 8, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $60 price target.
See today’s analyst top recommended stocks >>
Supernus Pharmaceuticals’ market cap is currently $1.76B and has a P/E ratio of 17.66. The company has a Price to Book ratio of 3.67.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SUPN in relation to earlier this year. Last month, John Siebert, a Director at SUPN bought 10,000 shares for a total of $91,300.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy.
